VALNEVA
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.
VALNEVA
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Saint-herblain, Pays De La Loire, France
Country:
France
Website Url:
http://www.valneva.com
Total Employee:
501+
Status:
Active
Contact:
33 2 28 07 37 10
Total Funding:
786.24 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro SPF Apple Mobile Web Clips Icon WordPress LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Ingenia Therapeutics
Ingenia Therapeutics provider of undisclosed products and services based in Cambridge, Massachusets.
KetoSwiss
KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Current Advisors List
Board_member
2022-01-01
Current Employees Featured
Juan Carlos Jaramillo Chief Medical Officer @ Valneva
Chief Medical Officer
2020-10-01
Hanneke Schuitemaker Chief Scientific Officer @ Valneva
Chief Scientific Officer
2024-05-01
Thomas Lingelbach President and Chief Executive Officer @ Valneva
President and Chief Executive Officer
Dipal Patel Chief Commercial Officer @ Valneva
Chief Commercial Officer
2022-11-01
Alain Munoz Scientific advisory Board @ Valneva
Scientific advisory Board
2019-09-01
Joshua Drumm Vice President and Global Investor Relations @ Valneva
Vice President and Global Investor Relations
2021-07-01
George Siber Member of SAB @ Valneva
Member of SAB
2019-11-01
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-02-10 | Crucell Sweden | Crucell Sweden acquired by Valneva | N/A |
Investors List
Horizon Europe
Horizon Europe investment in Grant - Valneva
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations investment in Grant - Valneva
Deerfield
Deerfield investment in Post-IPO Debt - Valneva
OrbiMed
OrbiMed investment in Post-IPO Debt - Valneva
Bpifrance
Bpifrance investment in Post-IPO Equity - Valneva
Deep Track Capital
Deep Track Capital investment in Post-IPO Equity - Valneva
Pfizer
Pfizer investment in Post-IPO Equity - Valneva
Deerfield
Deerfield investment in Post-IPO Debt - Valneva
OrbiMed
OrbiMed investment in Post-IPO Debt - Valneva
Scottish Enterprise
Scottish Enterprise investment in Grant - Valneva
Key Employee Changes
| Date | New article |
|---|---|
| 2024-05-20 | Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer |
| 2023-03-02 | Valneva reports more data on Covid-19 vaccine; ClinChoice buys a CRO |
| 2022-11-17 | Valneva Appoints Dipal Patel as Chief Commercial Officer |
Official Site Inspections
http://www.valneva.com Semrush global rank: 1.15 M Semrush visits lastest month: 23.84 K
- Host name: sl71.web.hostpoint.ch
- IP address: 217.26.52.50
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
Valneva.com lookup results from whois.gandi.net server:
- Domain created: 7th-Dec-2012
- Domain updated: 6th-Nov-2024
- Domain expires: 7th-Dec-2025 0 Years, 228 Days left
- Website age: 12 Years, 136 Days
- Registrar Domain ID: 1764655223_DOMAIN_COM-VRSN
- Registrar Url: http://www.gandi.net
- Registrar WHOIS Server: whois.gandi.net
- Registrar Abuse Contact Email: abuse@support.gandi.net
- Registrar Abuse Contact Phone: +33.170377661
- Name server:
- MAIL7.VALNEVA.COM
- NS1.VALNEVA.COM
- NS2.VALNEVA.COM
- NS4.VALNEVA.COM
More informations about "Valneva"
About Us - Valneva
Jul 11, 2019 Valneva at a glance. 3. Commercial vaccines. €153.7m. Total revenues in 2023. 3. Unique vaccine development programs. Integrated differentiated clinical and pre-clinical assets. robust commercial portfolio. …See details»
Valneva SE - Wikipedia
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston , …See details»
Investors - Valneva
Jul 11, 2019 Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our strategy is based on an integrated …See details»
Valneva - Crunchbase Company Profile & Funding
Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for …See details»
Our Global Operations - Valneva annual business report
Mar 20, 2024 Valneva’s manufacturing network has been operating and producing licensed vaccines for more than ten years. The two main manufacturing sites in Scotland and Sweden have recently been expanded …See details»
Valneva - Org Chart, Teams, Culture & Jobs - The Org
View Valneva's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Letter from the CEO - Valneva annual business report
At Valneva we focus on where we can make a positive impact on global health by providing prophylactic vaccines that make a difference, limiting the threat of infectious diseases. We …See details»
Our strategy - Valneva annual business report
Valneva aims to be a globally recognized vaccine company by innovating today and preserving tomorrow. Advancing vaccines for better lives. A specialty vaccine company. Our strategy is based on an integrated business model that has …See details»
Valneva Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Valneva has 5 employees across 8 locations and €144.62 m in annual revenue in FY 2023. See insights on Valneva including office locations, competitors, revenue, financials, …See details»
Compliance - valneva.us
Valneva is committed to conducting business ethically and responsibly and in compliance with applicable laws, rules and regulations. ... If you need detailed information, please feel free to …See details»
Valneva Responds to French Government’s Call for Vaccine Supply …
Mar 24, 2025 Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the …See details»
Valneva: Culture - LinkedIn
We are an international and multicultural organization that prides itself in providing our workforce the opportunity for personal growth and development. ... Valneva is a specialty vaccine …See details»
12 Analysts Assess Valneva: What You Need To Know
1 day ago Revenue Growth: Valneva's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of …See details»
Valneva and LimmaTech Announce First Vaccination in Phase 2 …
Apr 9, 2025 Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a …See details»
Corporate Social Responsibility - Valneva annual business report
Valneva is an international and multicultural company that prides itself on offering its workforce the opportunity for personal growth and development. Respecting the Environment Aware that …See details»
Home - Valneva
Jul 11, 2019 Valneva est une société spécialisée dans le développement, la production et la commercialisation de vaccins prophylactiques contre des maladies infectieuses générant …See details»
Valneva Receives First Marketing Authorization for IXCHIQ® in a ...
1 day ago Saint Herblain (France), April 14, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory …See details»
Valneva SE: Initiating Hold Rating Based On Potentially Limited …
6 hours ago Valneva shares have traded within a range of roughly $4 and $8 over the past 12 months. The stock reached a high in mid-2024. It declined later in the year and now currently …See details»
Our Strategy - Valneva
R&D. Investing in innovative R&D programs to meet unmet medical needs. Valneva is focused on utilizing its proven and validated product development capabilities to rapidly advance solutions …See details»
Valneva receives Brazilian marketing authorization for single-dose ...
6 hours ago Valneva SE, a specialty vaccine company, announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine …See details»